HealthSnap logo

HealthSnap

Miami, FL Healthcare Technology Private

HealthSnap is a Miami-based virtual care management SaaS platform that enables healthcare providers and health systems to deploy Remote Patient Monitoring (RPM) and Chronic Care Management (CCM) programs. The platform provides chronic disease-agnostic cellular-enabled monitoring devices shipped directly to patients with no setup, AI-guided care coordination, virtual care delivery, patented billing tools, and population analytics. HealthSnap also operates a national clinical care management services team that handles patient outreach, enrollment, adherence tracking, and revenue cycle workflows on behalf of provider clients.

Overview

Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.

Founded

2015

Employees

201–500

Total Funding

$48.5M

4 rounds

Funding

Total raised $48.5M across 4 rounds

Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.

Last updated 05-22-2026

Latest Round

Type

Series B

Date

February 21, 2024

Amount

$25M

Valuation

Lead Investors

Sands Capital
DateRoundAmount RaisedValuationLead Investors
February 21, 2024 Series B $25M Sands Capital
May 17, 2023 Series A $9M Asclepius Growth Capital
November 2021 Seed $5M OPKO Health

Prominent Investors

Unity Point Health Tampa General Hospital Steve Cashman Asclepius Growth Capital Mac Donald Ventures Florida Funders

Leadership

  • Samson Magid

    Co-Founder & Chief Executive Officer

    LinkedIn
  • Wesley Smith

    Co-Founder & Chief Scientific Officer

  • Chase Preston

    Co-Founder & Chief Product Officer

Competitors

Competitor list is illustrative and may be incomplete, stale, or erroneous.

  • Cadence

    RPM and chronic care management platform combining cellular-connected devices with clinical monitoring teams for health systems, operating on a risk-based partnership model.

  • Optimize Health

    Seattle-based remote patient monitoring SaaS providing connected devices and a HIPAA-compliant clinical platform to physician practices and health systems.

  • Health Recovery Solutions

    RPM platform serving hospital systems, home health agencies, and post-acute care providers with telehealth and remote monitoring tools.

  • Vivify Health

    Connected care management platform offering RPM, virtual visits, and care plans across acute, chronic, and post-discharge populations.

  • Accuhealth

    Texas-based remote patient monitoring company providing cellular devices, 24/7 clinical monitoring, and chronic care management services to providers.

  • TimeDoc Health

    Virtual care management platform combining CCM, RPM, and behavioral health services with care coordination staff for primary care providers and FQHCs.

HealthSnap Investment FAQ

Public status and buying access

No. HealthSnap is a private company and does not have a public stock ticker or trade on a public stock exchange. Its shares are generally held by founders, employees, investors, and other private shareholders. Buyers and sellers may be able to transact in HealthSnap shares through private secondary transactions, but any transaction depends on share availability, buyer and seller agreement, transfer restrictions, company approval rights, and any applicable right of first refusal. There is no guarantee that HealthSnap will complete an IPO or other liquidity event.

Yes, it is sometimes possible to buy HealthSnap shares pre-IPO through private secondary transactions. This depends on finding a willing seller, company approval, and satisfying any transfer restrictions or rights of first refusal.

Buyers interested in buying HealthSnap shares on the secondary market typically do so through SetterVC and other secondary-market platforms, subject to eligibility requirements, share availability, transfer restrictions, and issuer approval. Buyers may need to satisfy sophistication, accreditation, institutional, platform, regulatory, or other eligibility requirements before participating. Once eligible, buyers may be able to view listings, make bids, and work with a licensed broker through the transaction process. Buyers should ensure they have appropriate legal and financial advisors guiding them before completing any transaction.

Valuation and funding

HealthSnap's latest disclosed funding round was a Series B round in February 21, 2024. The round raised approximately $25M, with Sands Capital listed as disclosed lead or major investors. Primary funding rounds are different from secondary transactions: in a primary round, capital goes to the company, while in a secondary transaction, investors buy existing shares from current shareholders. Funding-round data reflects publicly reported or collected information and may be incomplete.

HealthSnap has raised approximately $48.5M in disclosed funding across 4 rounds. These figures reflect primary capital raised by the company and do not include every possible secondary transaction, undisclosed round, debt facility, or private transfer. Reported funding totals can change as new rounds are announced or older round details are corrected. Eligible users can use SetterVC to track HealthSnap's funding history alongside private-market activity where available.

HealthSnap's disclosed investors include Unity Point Health, Tampa General Hospital, Steve Cashman, Asclepius Growth Capital, Mac Donald Ventures and Florida Funders. Investor lists are based on public reporting, company announcements, and collected funding-round data, and may be incomplete. Participation in a prior funding round does not mean those investors are currently buying or selling shares. On SetterVC, eligible users can review HealthSnap's funding history, valuation history, and private-market activity alongside other venture-backed companies.

Market context

HealthSnap's most-cited competitors include Cadence, Optimize Health, Health Recovery Solutions, Vivify Health, Accuhealth and TimeDoc Health. Investors often compare these companies by sector, product focus, valuation, funding raised, growth signals, investor base, and private-market activity.

Secondary-market demand for HealthSnap shares can be affected by company performance, revenue growth, profitability, funding history, valuation, investor interest, sector momentum, public-market conditions, expected timing of a liquidity event, and the availability of shares for sale. Demand can also be affected by transfer restrictions, company approval rights, right of first refusal processes, limited information, and the price expectations of buyers and sellers. Strong demand does not guarantee strong pricing, liquidity, or investment returns. Weak demand does not necessarily reflect the company's long-term prospects. Demand signals should not be treated as a recommendation or prediction of investment performance. Buyers and sellers should treat demand signals as informational and conduct their own diligence before transacting.

Selling and transaction mechanics

Sellers often rely on intermediaries and platforms, such as SetterVC and other secondary-market platforms, to identify potential buyers. The exact process varies by company and transaction, but sellers often begin by confirming their ownership, desired price, transferability, and any company approval or notice requirements. If the seller agrees with a buyer on acceptable price and terms, the company may need to be notified through a share transfer notice or similar process. If a right of first refusal, company approval right, or other transfer restriction applies, the seller may need to wait until that process is completed. The parties may then execute a purchase and sale agreement, complete required transfer documentation, and close if all required conditions are satisfied. Sellers should always seek proper legal and financial advice before completing the transaction.

Yes, current and former HealthSnap employees, early investors, and other existing shareholders may be able to sell vested shares before an IPO through a private secondary sale. This is not automatic; it depends on whether the shareholder has transferable shares, whether there is buyer demand, and whether the company's governing documents permit the transfer. Many companies require prior notice, company approval, or a right of first refusal before shares can be sold. Sellers should also seek proper legal and financial advice before proceeding.

A HealthSnap secondary transaction usually involves an existing shareholder selling shares to a buyer before a public listing. The buyer and seller typically agree on price, number of shares, share class, and closing conditions. The seller may then need to notify HealthSnap through a share transfer notice or similar process. If HealthSnap or existing investors have approval rights, transfer restrictions, or a right of first refusal, those steps may need to be completed before the transfer can close. The parties typically enter into a purchase and sale agreement, complete any required transfer documentation, and close only if the necessary conditions are satisfied. Timing and certainty can vary by company and transaction.

In most private secondary transactions, parties commonly use a purchase and sale agreement that outlines price, terms, and conditions. They may also use share transfer documentation, often a stock transfer notice, share transfer notice, transfer instruction, or similar document, along with any required company approval or right of first refusal materials. Proof of ownership, such as a cap table entry, share certificate, brokerage statement, issuer confirmation, or administrator confirmation, may also be important. Buyers often request recent company financials, but private companies may limit disclosure. Since every deal varies, buyers and sellers should consult legal and financial advisors to understand which documents are needed.

Risk, diligence, and investor caution

Buying HealthSnap shares pre-IPO is risky. Shares are illiquid, no IPO or liquidity event is guaranteed, valuations can change, transfers may require company approval, and private companies may provide limited financial disclosure. Be prepared for total loss. SetterVC and Setter Capital do not provide due diligence, legal, tax, accounting, valuation, or investment advice. Buyers must conduct their own due diligence, verify information, and seek independent legal and investment advice before proceeding.

Private secondary shares are typically illiquid. Unlike public stocks, there is no active public market, so selling them can be difficult and time-consuming. Sales depend on finding a willing buyer and often require company approval. Investors should be prepared to hold the shares for an extended period, with no guarantee of a future sale. Always assess your need for liquidity before investing.

SetterVC and Setter Capital do not provide due diligence, legal, tax, accounting, valuation, or investment advice. Buyers must conduct their own due diligence, including verifying ownership, transferability, legal structure, company approval, and assessing the company's prospects. SetterVC and Setter Capital do not provide advice on whether an investment is good, what price to pay, or what the best bid or ask is. SetterVC and Setter Capital may share documents in some circumstances, but it does not guarantee their accuracy or completeness. Due diligence is essential. Seek legal and investment advice as needed.

Before buying HealthSnap shares, a buyer should try to review the share class, price per share, implied valuation, transfer restrictions, ROFR process, company approval rights, seller ownership evidence, recent financing or tender-offer information, available financial information, information rights, resale restrictions, tax considerations, and expected liquidity paths. Not all information may be available for a private company. Buyers should confirm available diligence, process details, and information needs with their own legal, tax, and investment advisers.

SPVs carry risks. Examples include the need to confirm the company allows SPV-based transfers, verify that the SPV truly owns the shares or interests it claims to own, and ensure it has not sold more interests than it holds. Due diligence is essential. Seek legal and investment advice as needed.

Forward contracts carry risks. Examples include the seller refusing to transfer the shares at the future date, even if the seller owns them, the seller going bankrupt with creditors claiming the shares, or the seller committing the same shares to multiple parties. Due diligence is essential. Seek legal and investment advice as needed.

Access live market data

Sign Up

Data collected with AI, which can make mistakes. Please double-check this information.